ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Lonza to boost output of highly potent drug actives

by Rick Mullin
June 21, 2019 | APPEARED IN VOLUME 97, ISSUE 25

 

09725-buscon15-lonzacxd.jpg
Credit: Lonza
A fermenter at Lonza's site in Visp

Lonza plans to increase capacity for highly potent active pharmaceutical ingredients (HPAPIs) by adding two 4 m3 multipurpose production lines at its main site in Visp, Switzerland, by July 2020. The expansion will support a long-term manufacturing agreement with AstraZeneca as well as overall increased HPAPI demand for cancer therapies. “Oncology continues as the leading indication in biopharma,” says Lee Newton, head of Lonza’s API business.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment